Publications in collaboration with researchers from University of Pittsburgh (1)

2017

  1. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

    The Lancet, Vol. 390, Núm. 10094, pp. 555-566